pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,190 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1208Endpoints914BioPharma Dive353BioSpace335Fierce Biotech313onclive165raps110globenewswire health73
therapy area
allOncology8013Rare Disease1921Cardiology1862Immunology1536Hematology1353Pulmonology1244Vaccines
  • Experts discuss next-generation pathology and precision care for non-small cell lung cancer in new CME podcast
    The CME podcast released on May 6, 2026 brings together Sanja Dacic, Isabel Preeshagul, and Soo-Ryum (Stewart) Yang to review recent advances in pathology for non-small cell lung cancer. The exper…
    onclive · 4mo agoNeutral↗ source
  • Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
    Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
    onclive · 4mo agoNeutral↗ source
← prev
page 82 of 88
next →
fda recalls71
fda medwatch61
fda press38
1243
Psychiatry & CNS882
Ophthalmology518
Pain500
Endocrinology & Metabolism491
Infectious Disease455
Iopofosine I-131 shows high response rates and durable disease control in Waldenstrom macroglobulinemia trial
The 12‑month follow‑up from the CLOVER‑WaM study reports that patients receiving Iopofosine I‑131 achieved strong clinical activity in Waldenstrom macroglobulinemia. In the per‑protocol group, the…
onclive · 4mo agoPositive readoutPositive↗ source
  • Cytokinetics' Myqorzo meets primary goals in Phase 3 trial for non-obstructive hypertrophic cardiomyopathy
    Cytokinetics announced that its experimental therapy Myqorzo achieved its primary endpoints in a Phase 3 study of patients with non-obstructive hypertrophic cardiomyopathy (HCM). The trial showed…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Vertex Q1 revenue slightly below forecasts as key drug sales miss estimates, but Alyftrek revenue surges
    Vertex Pharmaceuticals reported first‑quarter revenue of about $3 billion, falling just short of Wall Street expectations. The modest miss left the stock largely unchanged on the day of the release…
    BioPharma Dive · 4mo agoEarningsNeutral↗ source
  • Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancer
    Dr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…
    onclive · 4mo agoNeutral↗ source
  • Pfizer CEO Albert Bourla rules out any transformative merger plans
    On the May 5, 2026 earnings call, Pfizer chief Albert Bourla was asked whether the company was considering a transformative merger in the near or medium term. Bourla answered that Pfizer has no pl…
    Endpoints · 4mo agoNeutral↗ source
  • BioNTech plans to cut up to 1,860 manufacturing jobs as it scales down production footprint
    BioNTech announced in its first‑quarter earnings release that it will reduce its manufacturing footprint. The company said the restructuring could affect as many as 1,860 employees working in its…
    Endpoints · 4mo agoLayoffsNegative↗ source
  • Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's Tepezza
    Viridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Pfizer halts final Trillium study, redirects R&D funds to cancer and obesity programs
    Pfizer announced it is ending the last clinical trial that originated from its 2021 purchase of Trillium Therapeutics. The company said the decision will free up cash that will be redirected to a…
    Endpoints · 4mo agoNeutral↗ source
  • Madrigal secures fourth MASH partnership, snapping up Arrowhead drug passed over by J&J
    Madrigal Pharmaceuticals announced its latest collaboration, marking the fourth deal focused on metabolic dysfunction-associated steatohepatitis (MASH) within a ten‑month span. The agreement bring…
    Endpoints · 4mo agoDealPositive↗ source
  • Emerging Antibody-Drug Conjugates Target New Endometrial Cancer Antigens Beyond HER2
    Faculty members highlighted a growing interest in endometrial cancer therapies that go beyond the HER2 pathway. They noted that the field is expanding its focus to a broader set of molecular target…
    onclive · 4mo agoPositive↗ source
  • Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setback
    Cytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancer
    Dr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer. She notes that, as of 2026, ther…
    onclive · 4mo agoNeutral↗ source
  • Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancer
    HS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhib…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Microbiome startup Kanvas Biosciences secures $48 million to advance immunotherapy and malnutrition therapies
    Kanvas Biosciences announced it has closed a $48 million financing round to fund development of microbiome-based treatments targeting cancer immunotherapy response and severe malnutrition. The cap…
    Endpoints · 4mo agoDealPositive↗ source
  • J&J advances IBD combo to Phase 3 despite Phase 2 setbacks
    Johnson & Johnson said it will advance its experimental inflammatory bowel disease therapy, JNJ-4804, into Phase 3 trials even though the drug failed to meet primary endpoints in two Phase 2 studie…
    Endpoints · 4mo agoNegative readoutNeutral↗ source
  • Phase 3 STRIKE trial to assess disease-free survival of adjuvant tivozanib plus pembrolizumab in high-risk RCC
    Dr. Bradley McGregor, director of clinical research at the Lank Center of Genitourinary Oncology, outlined the key objectives of the ongoing phase 3 STRIKE trial (NCT06661720). The study evaluates…
    onclive · 4mo agoNeutral↗ source
  • Cytospire secures $83 million to develop pan-gamma delta T-cell engagers
    Cytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Parsley Health joins nationwide insurance networks, expanding access to its primary-care model
    Parsley Health, a decade-old primary-care startup that originally operated on a cash-pay model, announced that it is now in-network with insurers across the United States. The move marks a shift f…
    Endpoints · 4mo agoPositive↗ source
  • Top Breast Cancer Experts Highlight Key Abstracts Ahead of 2026 ESMO Congress in Berlin
    Leading breast oncologists are sharing the abstracts they consider most important as the European Society for Medical Oncology (ESMO) Breast Cancer Congress approaches in Berlin from May 6 to 8, 20…
    onclive · 4mo agoNeutral↗ source
  • Takeda advances gene therapy, UK cancer biotech raises $83M, and new blood test may guide Wegovy use
    A Cleveland‑based biotech announced that a previously halted gene therapy program has been revived, offering a potential new option for patients as the company pursues additional studies. Takeda r…
    Endpoints · 4mo agoNeutral↗ source
  • Swiss pharma manufacturing remains steady despite tariff threats, impact may take years
    Swiss biotech day event highlighted that pharma manufacturing in Switzerland shows no immediate disruption from geopolitical tensions or potential tariffs. Industry representatives said that while…
    Endpoints · 4mo agoNeutral↗ source
  • Healthcare giants increasingly develop in-house AI tools instead of buying from startups
    Panelists at the Digital Healthcare Innovation Summit in Boston highlighted a growing shift among large health‑care organizations toward creating their own artificial‑intelligence solutions. Rather…
    Endpoints · 4mo agoNeutral↗ source
  • JAK inhibitor sequencing and transplant timing in myelofibrosis discussed at 2026 conference
    Dr. Andrew Kuykendall of Moffitt Cancer Center explained how doctors decide the order of JAK inhibitor therapies and when to consider allogeneic stem cell transplant for myelofibrosis patients. At…
    onclive · 4mo agoNeutral↗ source